We are sharing a very special blog today from one of our amazing fundraisers - Evan Moffitt, son of one of our Trustees, Heather. He has chosen to share his personal story with us, and we are so proud and grateful to him for the opportunity to hear from him directly ..read more

Make 2nds Count is proud to announce that £219,560 in research funding, across 3 years, has been awarded to a new study taking place across the UK & Ireland investigating screening secondary breast cancer patients for brain metastases before they become symptomatic. Recruitment of patients will start in 2024 ..read more

Breast cancer spreading to the brain (brain metastases, or brain mets) can occur in up to 25-55% of HER2-positive secondary breast cancer patients. Brain metastases in secondary breast cancer patients is treated with radiotherapy and/or surgery ..read more

The Scottish Medicines Consortium (SMC) has announced that trastuzumab deruxtecan (Enhertu®) has been approved for usage within NHSScotland for metastatic HER2-positive breast cancer patients who have received one or more prior anti-HER2-based regimens. The National Institute for Health and Care Excellence (NICE) approved trastuzumab deruxtecan for this same patient cohort in NHS England & Wales in December 2022 ..read more

Can you tell me more about why you chose to fundraise for us? I am a big believer that sometimes the smaller charities often get overlooked and therefore do not get the same funding as some of the larger charities ..read more

Make 2nds Count is aware that founder Lisa Fleming has spoken on social media about legal action she has brought against the charity. The charity will not comment about the active tribunal other than to confirm that we refute all aspects of the claim ..read more

Sacituzumab govitecan-hziy (known by the trade name TRODELVY®) was approved for NHS usage in 2022 for secondary TNBC patients, who have had two or more systemic therapies (such as chemotherapies), with at least one of these being for advanced disease. TRODELVY® was approved for this demographic of secondary TNBC patients because a phase 3 clinical trial (known as the ASCENT trial) showed positive patient outcomes ..read more

Can you tell me a little about yourself? I'm 25 years old and live in Newcastle Upon Tyne with my boyfriend Jake and our German Shepherd Luna ..read more

The Food and Drug Administration (FDA) is responsible for approving drugs for disease treatment in America. Typically, before a new cancer drug is approved for usage in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA), which has a separate approval process, the drug will initially get approved for usage in America by the FDA first ..read more

The government has scrapped the specific NHS England 10-year cancer strategy for a new blended 5-year Major Conditions Strategy. England’s health and social care secretary, Steve Barclay, told the House of Commons on 24 January that the Department of Health and Social Care is currently developing a new 5-year Major Conditions Strategy that will tackle the major conditions that contribute to the burden of disease in England ..read more